The tibetan medicine Zuozhu-Daxi can prevent Helicobacter pylori induced-gastric mucosa inflammation by inhibiting lipid metabolism

Yanyan Shi; Jing Ning; Kelsang Norbu; Xingzi Hou; Huiling Zheng; Hejun Zhang; Wei Yu; Feng Zhou; Yuan Li; Shigang Ding; Qingying Zhang

doi:10.1186/s13020-022-00682-9

The tibetan medicine Zuozhu-Daxi can prevent Helicobacter pylori induced-gastric mucosa inflammation by inhibiting lipid metabolism

Chin Med. 2022 Nov 8;17(1):126. doi: 10.1186/s13020-022-00682-9.

Authors

Yanyan Shi^#¹, Jing Ning^#², Kelsang Norbu^#³, Xingzi Hou⁴, Huiling Zheng², Hejun Zhang², Wei Yu⁵, Feng Zhou³, Yuan Li², Shigang Ding⁶, Qingying Zhang⁷

Affiliations

¹ Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, 100191, People's Republic of China.
² Department of Gastroenterology, Peking University Third Hospital, No. 49, Garden North Road, Haidian District, Beijing, 100191, People's Republic of China.
³ Department of Research and Development, Tibet Ganlu Tibetan Medicine Co., Ltd, Lhasa, 850000, People's Republic of China.
⁴ Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University Health Science Center, No. 38, Xueyuan Road, Haidian District, Beijing, 100191, People's Republic of China.
⁵ Department of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining, 272000, People's Republic of China.
⁶ Department of Gastroenterology, Peking University Third Hospital, No. 49, Garden North Road, Haidian District, Beijing, 100191, People's Republic of China. dingshigang222@163.com.
⁷ Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University Health Science Center, No. 38, Xueyuan Road, Haidian District, Beijing, 100191, People's Republic of China. qyzhang@bjmu.edu.cn.

^# Contributed equally.

Abstract

Background: Tibetan medicine has been used in clinical practice for more than 3800 years. Zuozhu-Daxi (ZZDX), a classic traditional Tibetan medicine, has been proved to be effective in the treatment of digestive diseases, such as chronic gastritis, gastric ulcer, etc. Helicobacter pylori (H. pylori), one of the most common pathogenic microbes, is regarded as the most common cause of gastritis. Researching on the effects of ZZDX on H. pylori-induced gastric mucosa inflammation could provide more evidences on H. pylori treatment and promote the development of Tibetan medicine. This study aimed to explore whether ZZDX could rescue H. pylori-induced gastric mucosa inflammation and its mechanism.

Methods: Male C57BL/6 mice were infected with H. pylori, and orally treated with ZZDX to rescue gastric mucosa inflammation induced by H. pylori infection. Pathology of gastric mucosa inflammation was evaluated under microscopy by hematoxylin-eosin (HE) staining. The infection status of H. pylori was evaluated by immunohistochemical (IHC) staining. The reactive oxygen species (ROS) level in serum was evaluated using a detection kit. IL-1α, IL-6, and PGE2 expression levels in serum were measured using ELISA. IL-1α, IL-8, TNF-α, and NOD1 expression levels in gastric tissues were measured using real-time PCR. RNA sequencing and gene certification of interest were performed to explore the mechanisms in vivo and in vitro.

Results: The results showed that ZZDX could significantly inhibit H. pylori-induced gastric mucosa inflammation using HE staining. IL-1α, IL-6, and PGE2 expression levels in serum were significantly decreased after treatment with ZZDX. ZZDX treatment significantly decreased the mRNA expression of IL-8 induced by H. pylori infection in gastric tissues. Elovl4, Acot1 and Scd1 might be involved in the mechanisms of ZZDX treatment. However, the H. pylori infection status in the gastric mucosa was not reduced after ZZDX treatment.

Conclusions: ZZDX reversed gastric mucosal injury and alleviated gastric mucosa inflammation induced by H. pylori infection.

Keywords: Gastric mucosal inflammation; Gastric mucosal injury; Helicobacter pylori; Tibetan medicine; Zuozhu-Daxi.

Abstract

Grants and funding